$AIXN
AiXin Life International, Inc. Stock $aixn

$aixn Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224013947 Filed on April 08, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$26.39K	$792.1K	$4.090M
YoY Change	-96.5%	-33.78%	51.0%
Cost Of Revenue	$788.9K	$900.6K	$3.425M
YoY Change	20.76%	-11.28%	20.47%
Gross Profit	$62.67K	-$108.5K	$664.8K
YoY Change	-38.21%	-159.93%	-594.08%
Gross Profit Margin	237.51%	-13.7%	16.25%
Selling, General & Admin	$583.0K	$998.3K	$2.836M
YoY Change	-3.53%	41.56%	29.94%
% of Gross Profit	930.27%		426.61%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$106.3K	$100.7K	$410.7K
YoY Change	1.66%	-1.91%	121.32%
% of Gross Profit	169.62%		61.78%
Operating Expenses	$1.473M	$998.3K	$6.589M
YoY Change	12.71%	41.56%	24.83%
Operating Profit	-$621.2K	-$1.107M	-$2.499M
YoY Change	12.55%	111.16%	-2.75%
Interest Expense	$110.00	$150.00	$840.00
YoY Change	-62.07%	-87.9%	-82.79%
% of Operating Profit
Other Income/Expense, Net	$17.65K	$95.10K	$427.6K
YoY Change	-22.07%	1090.24%	-111.26%
Pretax Income	-$603.6K	-$1.012M	-$2.071M
YoY Change	14.03%	96.45%	-67.48%
Income Tax		$13.64K	$19.52K
% Of Pretax Income
Net Earnings	-$603.6K	-$1.025M	-$2.091M
YoY Change	13.93%	98.92%	-67.18%
Net Earnings / Revenue	-2287.58%	-129.43%	-51.12%
Basic Earnings Per Share	-$0.02		-$0.08
Diluted Earnings Per Share	-$0.02	-$0.04	-$0.08
COMMON SHARES
Basic Shares Outstanding	25.00M shares	25.00M shares	25.00M shares
Diluted Shares Outstanding	25.00M shares		25.00M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$305.0K	$443.8K	$443.8K
YoY Change	-38.62%	-13.01%	-13.01%
Cash & Equivalents	$305.0K	$443.8K	$443.8K
Short-Term Investments
Other Short-Term Assets	$285.2K	$173.0K	$173.0K
YoY Change	43.42%	-19.05%	-19.05%
Inventory	$459.4K	$441.1K	$593.7K
Prepaid Expenses
Receivables	$379.8K	$253.6K	$253.6K
Other Receivables	$102.4K	$12.40K	$33.47K
Total Short-Term Assets	$1.696M	$1.497M	$1.497M
YoY Change	-16.31%	-24.22%	-24.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.551M	$1.680M	$3.256M
YoY Change	-17.4%	-14.81%	9.61%
Goodwill
YoY Change
Intangibles	$3.398K	$3.917K
YoY Change	211.17%	208.67%
Long-Term Investments	$83.17K	$84.51K	$84.51K
YoY Change	-4.81%	-2.85%	-2.85%
Other Assets		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Assets	$3.763M	$3.345M	$3.345M
YoY Change	34.75%	8.78%	8.78%
TOTAL ASSETS
Total Short-Term Assets	$1.696M	$1.497M	$1.497M
Total Long-Term Assets	$3.763M	$3.345M	$3.345M
Total Assets	$5.459M	$4.842M	$4.842M
YoY Change	13.28%	-4.13%	-4.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$487.9K	$478.5K	$478.5K
YoY Change	10.83%	20.07%	20.07%
Accrued Expenses	$2.395M	$2.927M	$2.927M
YoY Change	-17.9%	-7.27%	-7.27%
Deferred Revenue
YoY Change
Short-Term Debt	$83.10K	$84.51K	$84.51K
YoY Change	-4.89%	-2.85%	-2.85%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.946M	$5.964M	$5.964M
YoY Change	10.15%	12.06%	12.06%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.902M	$789.5K	$789.5K
YoY Change	958.77%	305.43%	305.43%
Total Long-Term Liabilities	$1.902M	$789.5K	$789.5K
YoY Change	958.77%	305.43%	305.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.946M	$5.964M	$5.964M
Total Long-Term Liabilities	$1.902M	$789.5K	$789.5K
Total Liabilities	$7.848M	$6.754M	$6.754M
YoY Change	40.7%	22.42%	22.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$17.82M	-$17.22M
YoY Change	13.82%	12.92%
Common Stock	$250.00	$250.00
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.389M	-$1.912M	-$1.912M
YoY Change
Total Liabilities & Shareholders Equity	$5.459M	$4.842M	$4.842M
YoY Change	13.28%	-4.13%	-4.13%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$603.6K	-$1.025M	-$2.091M
YoY Change	13.93%	98.92%	-67.18%
Depreciation, Depletion And Amortization	$106.3K	$100.7K	$410.7K
YoY Change	1.66%	-1.91%	121.32%
Cash From Operating Activities	-$461.5K	-$1.172M	-$1.392M
YoY Change	-2.38%	452.9%	-14.3%
INVESTING ACTIVITIES
Capital Expenditures	$41.05K	$79.52K	$295.5K
YoY Change	2251.26%	-23.71%	88.54%
Acquisitions
YoY Change
Other Investing Activities		-$3.320K	-$3.320K
YoY Change		-99.91%	-99.9%
Cash From Investing Activities	-$41.05K	-$82.84K	-$302.8K
YoY Change	692.38%	-97.88%	-91.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$383.8K	1.210M	$1.560M
YoY Change	-12.29%	-240.14%	-165.3%
NET CHANGE
Cash From Operating Activities	-$461.5K	-1.172M	-$1.392M
Cash From Investing Activities	-$41.05K	-82.84K	-$302.8K
Cash From Financing Activities	$383.8K	1.210M	$1.560M
Net Change In Cash	-$126.0K	-44.63K	-$152.9K
YoY Change	236.23%	-99.11%	-98.08%
FREE CASH FLOW
Cash From Operating Activities	-$461.5K	-$1.172M	-$1.392M
Capital Expenditures	$41.05K	$79.52K	$295.5K
Free Cash Flow	-$502.5K	-$1.252M	-$1.688M
YoY Change	5.92%	295.82%	-5.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet		usd
CY2023Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	us-gaap	Goodwill Goodwill		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	AIXN	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2022	AIXN	Government Grant Income GovernmentGrantIncome		usd
CY2022	AIXN	Cash Disposed At Disposal Of Subsidiary CashDisposedAtDisposalOfSubsidiary		usd
CY2023	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2023	AIXN	Prepayment For Acquisition PrepaymentForAcquisition		usd
CY2022	AIXN	Proceeds From Government Grant ProceedsFromGovernmentGrant		usd
CY2022	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	AIXN	Acquisition Of Subsidiary AcquisitionOfSubsidiary		usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess		usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods		usd
CY2023Q4	us-gaap	Accrued Rent Current AccruedRentCurrent		usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent		pure
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Security12g Title Security12gTitle	Common Stock, $0.00001 par value
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	25656989	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24999945	shares
CY2023	dei	Auditor Firm AuditorFirmId	2851
CY2023	dei	Auditor Name AuditorName	KCCW Accountancy Corp
CY2023	dei	Auditor Location AuditorLocation	Diamond Bar, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	443758	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	510128	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	23208	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	109772	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	253586	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	562581	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	170831	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	42631	usd
CY2023Q4	us-gaap	Supplies Supplies	152563	usd
CY2022Q4	us-gaap	Supplies Supplies	168523	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	441098	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	499252	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1497444	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1975989	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1679675	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1971793	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3917	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1269	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	15556	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	84508	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	86992	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1576814	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	999285	usd
CY2023Q4	us-gaap	Assets Assets	4842358	usd
CY2022Q4	us-gaap	Assets Assets	5050884	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	172753	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	139502	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	49249	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	104100	usd
CY2023Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	2163066	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	2356490	usd
CY2023Q4	AIXN	Government Grant GovernmentGrant	923238	usd
CY2022Q4	AIXN	Government Grant GovernmentGrant	950371	usd
CY2023Q4	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	84508	usd
CY2022Q4	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	86992	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	864519	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	883583	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5964450	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5322347	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	789489	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	194725	usd
CY2023Q4	us-gaap	Liabilities Liabilities	6753939	usd
CY2022Q4	us-gaap	Liabilities Liabilities	5517072	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24999834	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24999834	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24999834	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24999834	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	250	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	250	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14975423	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14458583	usd
CY2023Q4	AIXN	Statutory Reserves StatutoryReserves	151988	usd
CY2022Q4	AIXN	Statutory Reserves StatutoryReserves	151988	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17220392	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15249858	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	181150	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	172849	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1911581	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-466188	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4842358	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5050884	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4089799	usd
CY2023	AIXN	Cost Of Goods And Service Sold CostOfGoodsAndServiceSold	1613950	usd
CY2022	AIXN	Cost Of Goods And Service Sold CostOfGoodsAndServiceSold	1103160	usd
CY2023	AIXN	Hotel Operating Costs HotelOperatingCosts	1811065	usd
CY2022	AIXN	Hotel Operating Costs HotelOperatingCosts	1739948	usd
CY2023	us-gaap	Selling Expense SellingExpense	888745	usd
CY2022	us-gaap	Selling Expense SellingExpense	787637	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1947294	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1395008	usd
CY2023	AIXN	Reversal Of Provision For Bad Debts ReversalOfProvisionForBadDebts	-43988	usd
CY2022	AIXN	Reversal Of Provision For Bad Debts ReversalOfProvisionForBadDebts	-119274	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	371540	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	371540	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	6588606	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	5278019	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-2498807	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2569459	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	838	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	4876	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	3823770	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	438348	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	51856	usd
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	11554	usd
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	31651	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	427632	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3798689	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2071175	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6368148	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19519	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1097	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2090694	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6369245	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	8301	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-537974	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2082393	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6907219	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.084
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.084
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.255
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.255
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24999834	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24999834	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24999842	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24999842	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	6069491	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	371540	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6369245	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-537974	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-466188	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-466188	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	371540	usd
CY2023	AIXN	Disposal Of Subsidiary DisposalOfSubsidiary	120160	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	145300	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2090694	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	8301	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1911581	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1911581	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2090694	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6369245	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	410690	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	185565	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-362	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-47762	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	45953	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	7770	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	54899	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	817179	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	837425	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	371540	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	371540	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	15152	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1858	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	3823770	usd
CY2023	AIXN	Government Grant Income GovernmentGrantIncome	369857	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	132455	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-109439	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	133513	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	103016	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-36240	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-150872	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	37275	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-24401	usd
CY2023	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-52010	usd
CY2022	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-137711	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-779599	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-710865	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-161393	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	289868	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1392259	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1624565	usd
CY2023	AIXN	Cash Disposed At Disposal Of Subsidiary CashDisposedAtDisposalOfSubsidiary	-3319	usd
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	446381	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	295487	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	156723	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4032	usd
CY2022	AIXN	Prepayment For Acquisition PrepaymentForAcquisition	3812027	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-302838	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3522369	usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	1048409	usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-2389593	usd
CY2023	AIXN	Proceeds From Government Grant ProceedsFromGovernmentGrant	369857	usd
CY2023	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	142200	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1560466	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2389593	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-18303	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-444426	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-152934	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7980953	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	619900	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8600853	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	466966	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	619900	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4367	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	71163	usd
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1 for 2 reverse stock split
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24999834	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2090694	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1392259	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1624565	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17220392	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	510128	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	443758	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zBXTQPXYCp4i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zn3ZC5j3Kezg">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing consolidated financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zMDCDUwG8Nn1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zSXBfBMCNLq2">Reclassification</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts have been reclassified to conform to the current period presentation and had no effect on previously reported consolidated net income (loss) or accumulated deficit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	7770	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	54899	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	80640	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	272550	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	272550	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	213787	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-47762	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	45953	usd
CY2022	AIXN	Acquisition Of Subsidiary AcquisitionOfSubsidiary	196164	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	135589	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	165227	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	8559	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	18127	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	80640	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	272550	usd
CY2023Q4	us-gaap	Property Plant And Equipment Salvage Value Percentage PropertyPlantAndEquipmentSalvageValuePercentage	0.05	pure
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	3823770	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zJx9QQaZ5rX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zCktIfWbVXxk">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The operations of the Company are in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, and by the general state of the PRC economy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has cash on hand and demand deposits in accounts maintained with state-owned banks within the PRC. Cash in state-owned banks is covered by insurance up to RMB <span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_uRMB_c20231231_zcowNYFXJYyg">500,000</span> ($<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_uUSD_c20231231_zJdxgegl6dL2" title="Cash FDIC insured amount">72,500</span>) per bank. The Company has not experienced any losses in such accounts and believes they are not exposed to any risks on its cash in these bank accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2023 and 2022, the Company had no customer that accounted for over <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zO5QpRYSKbbc" title="Concentration risk percentage1"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zfnGUVVy8Og5" title="Concentration risk percentage1">10</span></span>% of its total revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zS7QoutTVvjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, the Company had two suppliers that accounted for over 10% of its total purchases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B5_zoMX6dpB0ZY5" style="display: none">SCHEDULE OF CONCENTRATION OF RISK BY RISK FACTORS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Supplier</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net purchases for the<br/> year ended<br/> December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% of total purchase</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--PurchaseCost_pp0p0_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_zeQ0yfQR6Q14" style="width: 16%; text-align: right" title="Total purchases">250,999</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierAMember_z8woFNNhHjM7" style="width: 16%; text-align: right">14</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>B</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--PurchaseCost_pp0p0_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zYH1wiJPM124" style="text-align: right" title="Total purchases">195,202</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zHzInXvmDX0l" style="text-align: right">11</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company had two major suppliers that accounted for over 10% of its total purchases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supplier</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net purchases for the<br/> year ended<br/> December 31, 2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>% of total purchase</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 62%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_ecustom--PurchaseCost_pp0p0_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zsXBmsrmsqUk" style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right" title="Net purchases"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">189,150</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierBMember_zD613QtYoOHh" style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C (1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_987_ecustom--PurchaseCost_pp0p0_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_fKDEp_zZUN6NpN1L01" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net purchases"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">149,806</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierCMember_fKDEp_zlEmqKHPBuLa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Percentage of total purchase"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F07_zSILHXgbcRWg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zYEOYUJha8Y1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company purchased inventory from this supplier, Runcansheng, in the year ended December 31, 2022. The Company acquired all of the outstanding equity of Runcangsheng on September 30, 2022 (see Note 19).</span></td></tr> </table> <p id="xdx_8A8_zBnjk9Wws8K7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	500000
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	72500	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	15546	usd
CY2023Q4	AIXN	Payable For Equipment Purchase Current PayableForEquipmentPurchaseCurrent	30307	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4089799	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2708560	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	6588606	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5278019	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-2498807	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2569459	usd
CY2023Q4	us-gaap	Assets Assets	4842358	usd
CY2022Q4	us-gaap	Assets Assets	5050884	usd
CY2023Q4	us-gaap	Deposit Assets DepositAssets	8978	usd
CY2023Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	128378	usd
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	9490	usd
CY2023Q4	us-gaap	Estimated Insurance Recoveries EstimatedInsuranceRecoveries	8667	usd
CY2022Q4	us-gaap	Estimated Insurance Recoveries EstimatedInsuranceRecoveries	10124	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	24808	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	7471	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	170831	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	42631	usd
CY2023Q4	us-gaap	Supplies Supplies	152563	usd
CY2022Q4	us-gaap	Supplies Supplies	168523	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	114005	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	62462	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	15315	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	521	usd
CY2023Q4	AIXN	Drugs Pharmaceutical And Nutritional Products DrugsPharmaceuticalAndNutritionalProducts	324588	usd
CY2022Q4	AIXN	Drugs Pharmaceutical And Nutritional Products DrugsPharmaceuticalAndNutritionalProducts	412129	usd
CY2023Q4	AIXN	Inventory Food And Beverage Hotel Supplies And Consumables Gross InventoryFoodAndBeverageHotelSuppliesAndConsumablesGross	81969	usd
CY2022Q4	AIXN	Inventory Food And Beverage Hotel Supplies And Consumables Gross InventoryFoodAndBeverageHotelSuppliesAndConsumablesGross	82646	usd
CY2022Q4	AIXN	Payable For Equipment Purchase Current PayableForEquipmentPurchaseCurrent	32278	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	250505	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	233894	usd
CY2023Q4	us-gaap	Deposit Liability Current DepositLiabilityCurrent	10986	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	520562	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	573073	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	79464	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	73821	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	441098	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	499252	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3010372	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2928342	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1330697	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	956549	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1679675	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1971793	usd
CY2023	us-gaap	Depreciation Depreciation	409351	usd
CY2022	us-gaap	Depreciation Depreciation	183542	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	12516	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	8564	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8599	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7295	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3917	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1269	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1339	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2023	usd
CY2022Q4	us-gaap	Deposit Liability Current DepositLiabilityCurrent	11308	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	49249	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	104100	usd
CY2023Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	231983	usd
CY2022Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	270349	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	308768	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	307331	usd
CY2022Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	32746	usd
CY2023Q4	us-gaap	Construction Payable Current ConstructionPayableCurrent	1229775	usd
CY2022Q4	us-gaap	Construction Payable Current ConstructionPayableCurrent	1384674	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	100742	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	83910	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2163066	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2356490	usd
CY2021Q4	AIXN	Government Grant Contribution GovernmentGrantContribution	8000000
CY2021Q4	AIXN	Government Grant Contribution GovernmentGrantContribution	1194400	usd
CY2023Q4	AIXN	Government Grant GovernmentGrant	923238	usd
CY2023Q4	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	84508	usd
CY2022Q4	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	86992	usd
CY2023	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	Runcangsheng leases its office under an operating lease arrangement. The lease was expired as of December 31, 2023. In January 2024, the lease was renewed with the expiration date on December 31, 2024.
CY2023	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2024-12-31
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1576814	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	999285	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	864519	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	883583	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	789489	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	194725	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1654008	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1078308	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	817179	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	837425	usd
CY2023	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	779599	usd
CY2022	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	710865	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y11M26D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y5M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0475	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0475	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	921869	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	759052	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	37370	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8451	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3521	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1730263	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	76255	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1654008	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	864519	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	789489	usd
CY2023Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	86392	usd
CY2022Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	42	usd
CY2023Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	86392	usd
CY2022Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	42	usd
CY2023Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1776	usd
CY2022Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	165958	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1226885	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	236882	usd
CY2014Q2	us-gaap	Payments For Rent PaymentsForRent	5000
CY2014Q2	us-gaap	Payments For Rent PaymentsForRent	704	usd
CY2014Q2	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2028-05-28
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	4367	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-761	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4367	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-761	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	15152	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1858	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	15152	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1858	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19519	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1097	usd
CY2023Q4	AIXN	Deferred Tax Assets Accumulated Amortization DeferredTaxAssetsAccumulatedAmortization	13204	usd
CY2022Q4	AIXN	Deferred Tax Assets Accumulated Amortization DeferredTaxAssetsAccumulatedAmortization	15556	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13204	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	15556	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.033	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.038	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.252	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.250	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.002	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.009	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.000	pure
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2020Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one (1)-for-four (4) reverse stock
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	24999834	shares
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	371540	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	371540	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	301127	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y9M21D
CY2023	us-gaap	Other Income OtherIncome	369857	usd
CY2023	AIXN	Net Income Transfer Percentage NetIncomeTransferPercentage	0.10	pure
CY2023	AIXN	Capital Reserve Percentage CapitalReservePercentage	0.50	pure
CY2023	AIXN	Statutory Reserve Fund StatutoryReserveFund	0	usd
CY2022	AIXN	Statutory Reserve Fund StatutoryReserveFund	0	usd
CY2023	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_80C_eus-gaap--LossContingencyDisclosures_zS3o5C3dtsph" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18. <span id="xdx_82A_zSTqEKsIHwXi">OPERATING CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environments and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s sales, purchases and expenses are denominated in RMB and all of the Company’s assets and liabilities are also denominated in RMB. The RMB is not freely convertible into foreign currencies under the current law. In China, foreign exchange transactions are required by law to be transacted only by authorized financial institutions. Remittances in currencies other than RMB may require certain supporting documentation to affect the remittance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is, from time to time, involved in litigation incidental to the conduct of its business regarding merchandise sold, employment matters, and litigation regarding intellectual property rights.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2020, Jian Yiao (the “Plaintiff”) filed a complaint against Chengdu Aixintang Pharmacy Co., Ltd. (“Aixintang Pharmacy”, or the “Defendant”) in Zhangjiagang People’s Court in Jiangsu Province. The complaint alleges that Jian Yiao is entitled to $<span id="xdx_900_eus-gaap--LongTermPurchaseCommitmentAmount_c20201201__20201231_ziwq6ZbBH0Yd" title="Purchase commitment amount">392,305</span> (RMB <span id="xdx_908_eus-gaap--LongTermPurchaseCommitmentAmount_uRMB_c20201201__20201231_zxqaZ1lgp5u" title="Purchase commitment amount">2,500,000</span>) from Aixintang Pharmacy for not fulfilling the contractual obligation of a purchase agreement entered in March 2020 (the “Purchase Agreement”). Aixintang Pharmacy claimed that the Purchase Agreement was falsely entered by an employee through forged documents, and that Aixintang Pharmacy did not enter the Purchase Agreement. The Court determined that Aixintang Pharmacy breached the Purchase Agreement by not delivering the products ordered and ordered Aixintang Pharmacy to pay $<span id="xdx_909_eus-gaap--LitigationSettlementExpense_c20201201__20201231_z6JzB4OJw54g" title="Litigation settlement expense">392,305</span> (RMB <span id="xdx_905_eus-gaap--LitigationSettlementExpense_uRMB_c20201201__20201231_zFJZAwQhdNMa" title="Litigation settlement expense">2,500,000</span>) to the Plaintiff. In December 2020, Aixintang Pharmacy filed a motion of appeal in the Jiangsu Suzhou Intermediate People’s Court against the determination reached from the first trial.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2021, the judge in the Jiangsu Suzhou Intermediate People’s Court denied the Defendant’s motion and upheld the judgment from the first trial. In March 2021, Aixintang Pharmacy filed another motion of re-trial to the Jiangsu High People’s Court on the basis that the Purchase Agreement was forged, the motion was accepted by Jiangsu High People’s Court in July 2021. Due to the impact of COVID-19 pandemic, Aixintang Pharmacy was unable to provide any new evidence to the Jiangsu High People’s Court. Consequently, in September 2022, the Court rejected the Defendant’s motion and upheld the judgment rendered in the second trial.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2021, Jian Yiao applied for the first execution of the judgement; a total of $<span id="xdx_907_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_c20210401__20240430__srt--LitigationCaseAxis__custom--FirstExecutionOfJudgementMember_zdNu4daA2nM6" title="Litigation settlement amount">97,748</span> (RMB <span id="xdx_906_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_uRMB_c20210401__20240430__srt--LitigationCaseAxis__custom--FirstExecutionOfJudgementMember_z3oYSJUYvfIe" title="Litigation settlement amount">694,000</span>) was executed. On June 13, 2023, Jian Yiao applied for the restoration of execution. The total amount executed this time was $<span id="xdx_901_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_c20230613__20230613__srt--LitigationCaseAxis__custom--RestorationOfExecutionMember_zmcQ2CyghE8f" title="Litigation settlement amount">110,818</span> (RMB <span id="xdx_90D_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_uRMB_c20230613__20230613__srt--LitigationCaseAxis__custom--RestorationOfExecutionMember_zyIb1fRS8uy" title="Litigation settlement amount">786,800</span>), and the remaining amount including overdue interest of $<span id="xdx_900_eus-gaap--LitigationSettlementInterest_c20230613__20230613__srt--LitigationCaseAxis__custom--FirstExecutionOfJudgementMember_ziJarT6dwnKc" title="Litigation settlement interest">139,692</span> (RMB <span id="xdx_909_eus-gaap--LitigationSettlementInterest_uRMB_c20230613__20230613__srt--LitigationCaseAxis__custom--FirstExecutionOfJudgementMember_zDsz91QodFHe" title="Litigation settlement interest">991,800</span>) was not executed. As of March 27, 2024, the amount that was frozen from this case was $<span id="xdx_908_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_c20240327__20240327__srt--LitigationCaseAxis__custom--FrozenCaseMember_zM3yVcZQ13b9" title="Litigation settlement amount">35,672</span> (RMB <span id="xdx_902_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_uRMB_c20240327__20240327__srt--LitigationCaseAxis__custom--FrozenCaseMember_zQOAjyWjiw72" title="Litigation settlement amount">253,266</span>), the total amount executed was $<span id="xdx_907_eus-gaap--GainLossRelatedToLitigationSettlement_c20240327__20240327__srt--LitigationCaseAxis__custom--FrozenCaseMember_zXyt1Ay56hUj" title="Gain loss litigation settlement">212,412</span> (RMB <span id="xdx_905_eus-gaap--GainLossRelatedToLitigationSettlement_pn4n6_uRMB_c20240327__20240327__srt--LitigationCaseAxis__custom--FrozenCaseMember_zQxdv9ZHN9a3" title="Gain loss litigation settlement">1.51</span> million), and the bank accounts of Chengdu Aixin Tang Haichuan Pharmacy Co., Ltd and its three branches were still frozen as of this report date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2021, the Company and Mr. Quanzhong Lin agreed that Mr. Lin shall assume any losses arising from this legal proceeding. As such, the Company did not accrue contingent losses from this legal proceeding as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that current pending litigation will not have a material adverse effect on its consolidated financial position, results of operations or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2020Q4	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	392305	usd
CY2020Q4	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	2500000
CY2020Q4	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	392305	usd
CY2020Q4	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	2500000
CY2023	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	3168061	usd
CY2023	AIXN	Business Acquisitions Pro Forma Cost Of Goods And Services Sold BusinessAcquisitionsProFormaCostOfGoodsAndServicesSold	-5605508	usd
CY2023	AIXN	Business Acquisitions Pro Forma Loss From Operations BusinessAcquisitionsProFormaLossFromOperations	2437447	usd
CY2023	AIXN	Business Acquisitions Pro Forma Other Nonoperating Income Expense BusinessAcquisitionsProFormaOtherNonoperatingIncomeExpense	34839	usd
CY2023	AIXN	Business Acquisitions Pro Forma Income Tax Expense Benefit BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit	1097	usd
CY2023	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	2403705	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	169016	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1200000

Files In Submission

Name	View Source	Status
0001493152-24-013947-index-headers.html	Edgar Link	pending
0001493152-24-013947-index.html	Edgar Link	pending
0001493152-24-013947.txt	Edgar Link	pending
0001493152-24-013947-xbrl.zip	Edgar Link	pending
aixn-20231231.xsd	Edgar Link	pending
ex19-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex99-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
aixn-20231231_cal.xml	Edgar Link	unprocessable
aixn-20231231_def.xml	Edgar Link	unprocessable
aixn-20231231_lab.xml	Edgar Link	unprocessable
aixn-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AIXN
AiXin Life International, Inc. Stock $aixn

2024 Q1 Form 10-K Financial Statement

#000149315224013947 Filed on April 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIXN AiXin Life International, Inc. Stock $aixn

2024 Q1 Form 10-K Financial Statement

#000149315224013947 Filed on April 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIXN
AiXin Life International, Inc. Stock $aixn